The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest

S L Locatelli¹, G Careddu¹, G Inghirami^{2

3

4}, L Castagna¹, P Sportelli⁵, A Santoro^{1

6}, C Carlo-Stella^{1

7}

Affiliations

¹ Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.
² Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA.
³ Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy.
⁴ Department of Pathology, and NYU Cancer Center, New York University School of Medicine, New York, NY, USA.
⁵ TG Therapeutics, Inc., New York, NY, USA.
⁶ Humanitas University, Rozzano, Italy.
⁷ Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy.

S L Locatelli et al. Leukemia. 2016 Dec.

. 2016 Dec;30(12):2402-2405.

doi: 10.1038/leu.2016.224. Epub 2016 Aug 8.

S L Locatelli¹, G Careddu¹, G Inghirami^{2

3

4}, L Castagna¹, P Sportelli⁵, A Santoro^{1

6}, C Carlo-Stella^{1

7}

¹ Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.
² Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY, USA.
³ Department of Molecular Biotechnology and Health Science and Center for Experimental Research and Medical Studies (CeRMS), University of Torino, Torino, Italy.
⁴ Department of Pathology, and NYU Cancer Center, New York University School of Medicine, New York, NY, USA.
⁵ TG Therapeutics, Inc., New York, NY, USA.
⁶ Humanitas University, Rozzano, Italy.
⁷ Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy.

No abstract available

References